Vilanterol information

Vilanterol
Clinical data
License data	EU EMA: by INN;
Pregnancy; category	AU: B3; ;
ATC code	R03AK10 (WHO) (+fluticasone); R03AL03 (WHO) (+umeclidinium);
Legal status
Legal status	AU: S4 (Prescription only); UK: POM (Prescription only); US: ℞-only; In general: ℞ (Prescription only);
Identifiers
	IUPAC name 4-{(1R)-2-[(6-{2-[(2,6-Dichlorobenzyl)oxy]ethoxy}hexyl)amino]-1-hydroxyethyl}-2-(hydroxymethyl)phenol;
CAS Number	503068-34-6;
PubChem CID	10184665;
IUPHAR/BPS	7353;
ChemSpider	8360167;
UNII	028LZY775B;
KEGG	D09696;
ChEBI	CHEBI:75037;
ChEMBL	ChEMBL1198857;
CompTox Dashboard (EPA)	DTXSID80198318 ;
ECHA InfoCard	100.217.751
Chemical and physical data
Formula	C24H33Cl2NO5
Molar mass	486.43 g·mol−1
3D model (JSmol)	Interactive image;
	SMILES c1cc(c(c(c1)Cl)COCCOCCCCCCNC[C@@H](c2ccc(c(c2)CO)O)O)Cl;
	InChI InChI=1S/C24H33Cl2NO5/c25-21-6-5-7-22(26)20(21)17-32-13-12-31-11-4-2-1-3-10-27-15-24(30)18-8-9-23(29)19(14-18)16-28/h5-9,14,24,27-30H,1-4,10-13,15-17H2/t24-/m0/s1; Key:DAFYYTQWSAWIGS-DEOSSOPVSA-N;

Vilanterol (INN, USAN) is an ultra-long-acting β₂ adrenoreceptor agonist (ultra-LABA), which was approved in May 2013 in combination with fluticasone furoate for sale as Breo Ellipta by GlaxoSmithKline for the treatment of chronic obstructive pulmonary disease (COPD).^[1]^[2]. The combination is also approved for the treatment of asthma in Canada, Europe, Japan^[3] and New Zealand.^[4]

Vilanterol is available in following combinations:

with inhaled corticosteroid fluticasone furoate—fluticasone furoate/vilanterol (trade names Breo Ellipta (U.S., NZ), Relvar Ellipta (EU, RU, JPN))
with muscarinic antagonist umeclidinium bromide—umeclidinium bromide/vilanterol (trade name Anoro Ellipta)
with inhaled corticosteroid fluticasone furoate and muscarinic antagonist umeclidinium bromide—fluticasone furoate/umeclidinium bromide/vilanterol (trade name Trelegy Ellipta)

^ "FDA approves Breo Ellipta to treat chronic obstructive pulmonary disease". Food and Drug Administration. Retrieved 10 May 2013.
^ McKeage K (September 2014). "Fluticasone furoate/vilanterol: a review of its use in chronic obstructive pulmonary disease". Drugs. 74 (13): 1509–22. doi:10.1007/s40265-014-0269-6. PMID 25074268. S2CID 29379731.
^ Syed YY (March 2015). "Fluticasone furoate/vilanterol: a review of its use in patients with asthma". Drugs. 75 (4): 407–18. doi:10.1007/s40265-015-0354-5. PMID 25648266. S2CID 24563680.
^ Zealand (www.bka.co.nz), Site designed and developed by bka interactive ltd, Auckland, New (22 June 2019). "Fluticasone and vilanterol | Health Navigator NZ". Health Navigator New Zealand.{{cite web}}: CS1 maint: multiple names: authors list (link)

[FDA_Breo-1] "FDA approves Breo Ellipta to treat chronic obstructive pulmonary disease". Food and Drug Administration. Retrieved 10 May 2013.

[McKeage_2014-2] McKeage K (September 2014). "Fluticasone furoate/vilanterol: a review of its use in chronic obstructive pulmonary disease". Drugs. 74 (13): 1509–22. doi:10.1007/s40265-014-0269-6. PMID 25074268. S2CID 29379731.

[Syed_2015-3] Syed YY (March 2015). "Fluticasone furoate/vilanterol: a review of its use in patients with asthma". Drugs. 75 (4): 407–18. doi:10.1007/s40265-015-0354-5. PMID 25648266. S2CID 24563680.

[4] Zealand (www.bka.co.nz), Site designed and developed by bka interactive ltd, Auckland, New (22 June 2019). "Fluticasone and vilanterol | Health Navigator NZ". Health Navigator New Zealand.{{cite web}}: CS1 maint: multiple names: authors list (link)

Vilanterol information

and 25 Related for: Vilanterol information

Vilanterol

Umeclidinium bromide

List of GSK plc products

Fluticasone furoate

ATC code R03

Fluticasone

Ellipta

WHO Model List of Essential Medicines

Ketamine

Atropine

LSD

Dimenhydrinate

Risperidone

Beta blocker

Aripiprazole

Adrenaline

Salbutamol

Anticholinergic

Buspirone

Hyoscine butylbromide

Trazodone

Diphenhydramine

Tramadol

Mirtazapine

Acetylcholine

Clinical data

License data	EU EMA: by INN
Pregnancy category	AU: B3
ATC code	R03AK10 (WHO) (+fluticasone) R03AL03 (WHO) (+umeclidinium)
Legal status
Legal status	AU: S4 (Prescription only) UK: POM (Prescription only) US: ℞-only In general: ℞ (Prescription only)
Identifiers
IUPAC name 4-{(1R)-2-[(6-{2-[(2,6-Dichlorobenzyl)oxy]ethoxy}hexyl)amino]-1-hydroxyethyl}-2-(hydroxymethyl)phenol
CAS Number	503068-34-6
PubChem CID	10184665
IUPHAR/BPS	7353
ChemSpider	8360167
UNII	028LZY775B
KEGG	D09696
ChEBI	CHEBI:75037
ChEMBL	ChEMBL1198857
CompTox Dashboard (EPA)	DTXSID80198318
ECHA InfoCard	100.217.751
Chemical and physical data
Formula	C₂₄H₃₃Cl₂NO₅
Molar mass	486.43 g·mol⁻¹
3D model (JSmol)	Interactive image
SMILES c1cc(c(c(c1)Cl)COCCOCCCCCCNC[C@@H](c2ccc(c(c2)CO)O)O)Cl
InChI InChI=1S/C24H33Cl2NO5/c25-21-6-5-7-22(26)20(21)17-32-13-12-31-11-4-2-1-3-10-27-15-24(30)18-8-9-23(29)19(14-18)16-28/h5-9,14,24,27-30H,1-4,10-13,15-17H2/t24-/m0/s1 Key:DAFYYTQWSAWIGS-DEOSSOPVSA-N